$1.48
9.51% today
Nasdaq, Apr 03, 06:50 pm CET
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Sana Biotechnology Inc Stock price

$1.63
-0.80 32.92% 1M
-2.73 62.61% 6M
+0.00 0.00% YTD
-7.19 81.52% 1Y
-7.52 82.19% 3Y
-33.47 95.36% 5Y
-33.47 95.36% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.13 8.67%
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Key metrics

Market capitalization $366.79m
Enterprise Value $304.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.46
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-273.36m
Free Cash Flow (TTM) Free Cash Flow $-256.58m
Cash position $156.33m
EPS (TTM) EPS $-1.17
P/E forward negative
Short interest 36.34%
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Sana Biotechnology Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
100%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 17 17
37% 37%
-
-17 -17
37% 37%
-
- Selling and Administrative Expenses 39 39
5% 5%
-
- Research and Development Expense 200 200
7% 7%
-
-256 -256
9% 9%
-
- Depreciation and Amortization 17 17
37% 37%
-
EBIT (Operating Income) EBIT -273 -273
12% 12%
-
Net Profit -267 -267
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
PRNewsWire
about 8 hours ago
NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
2 days ago
NEW YORK , April 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc.  (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be ent...
Neutral
PRNewsWire
6 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212...
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 194
Founded 2018
Website www.sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today